JP2000506890A - 置換２，３―ベンゾジアゼピン―４―オンおよびその使用 - Google Patents
置換２，３―ベンゾジアゼピン―４―オンおよびその使用Info
- Publication number
- JP2000506890A JP2000506890A JP9533496A JP53349697A JP2000506890A JP 2000506890 A JP2000506890 A JP 2000506890A JP 9533496 A JP9533496 A JP 9533496A JP 53349697 A JP53349697 A JP 53349697A JP 2000506890 A JP2000506890 A JP 2000506890A
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- alkyl
- heteroaryl
- arylalkyl
- arylalkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- NRGGDWGRGDCVAF-UHFFFAOYSA-N 2,3-benzodiazepin-4-one Chemical class N1=NC(=O)C=C2C=CC=CC2=C1 NRGGDWGRGDCVAF-UHFFFAOYSA-N 0.000 title abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 106
- 238000011282 treatment Methods 0.000 claims abstract description 32
- 208000028867 ischemia Diseases 0.000 claims abstract description 14
- 208000002193 Pain Diseases 0.000 claims abstract description 13
- 230000009885 systemic effect Effects 0.000 claims abstract description 13
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 12
- 206010010904 Convulsion Diseases 0.000 claims abstract description 11
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 11
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 10
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 9
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 8
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 7
- 208000000094 Chronic Pain Diseases 0.000 claims abstract description 7
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 7
- 208000023105 Huntington disease Diseases 0.000 claims abstract description 7
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 238000001356 surgical procedure Methods 0.000 claims abstract description 7
- 206010002091 Anaesthesia Diseases 0.000 claims abstract description 6
- 201000010374 Down Syndrome Diseases 0.000 claims abstract description 6
- 208000013016 Hypoglycemia Diseases 0.000 claims abstract description 6
- 230000002411 adverse Effects 0.000 claims abstract description 6
- 230000037005 anaesthesia Effects 0.000 claims abstract description 6
- 230000036506 anxiety Effects 0.000 claims abstract description 6
- 230000006378 damage Effects 0.000 claims abstract description 6
- 230000002461 excitatory amino acid Effects 0.000 claims abstract description 6
- 239000003257 excitatory amino acid Substances 0.000 claims abstract description 6
- 230000002218 hypoglycaemic effect Effects 0.000 claims abstract description 6
- 210000005036 nerve Anatomy 0.000 claims abstract description 6
- 206010044688 Trisomy 21 Diseases 0.000 claims abstract description 5
- 208000002720 Malnutrition Diseases 0.000 claims abstract description 4
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 4
- 230000036461 convulsion Effects 0.000 claims abstract description 4
- 230000001071 malnutrition Effects 0.000 claims abstract description 4
- 235000000824 malnutrition Nutrition 0.000 claims abstract description 4
- 208000015380 nutritional deficiency disease Diseases 0.000 claims abstract description 4
- -1 al Quinyl Chemical group 0.000 claims description 174
- 150000001875 compounds Chemical class 0.000 claims description 169
- 125000003118 aryl group Chemical group 0.000 claims description 125
- 125000000623 heterocyclic group Chemical group 0.000 claims description 89
- 125000000217 alkyl group Chemical group 0.000 claims description 80
- 125000002837 carbocyclic group Chemical group 0.000 claims description 70
- 125000001072 heteroaryl group Chemical group 0.000 claims description 68
- 239000001257 hydrogen Substances 0.000 claims description 62
- 229910052739 hydrogen Inorganic materials 0.000 claims description 62
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 59
- 150000002431 hydrogen Chemical class 0.000 claims description 58
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 55
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 55
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 54
- 125000001188 haloalkyl group Chemical group 0.000 claims description 54
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims description 53
- 125000005312 heteroarylalkynyl group Chemical group 0.000 claims description 51
- 125000003342 alkenyl group Chemical group 0.000 claims description 44
- 125000005015 aryl alkynyl group Chemical group 0.000 claims description 44
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 32
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 29
- 125000000304 alkynyl group Chemical group 0.000 claims description 28
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims description 20
- 239000000651 prodrug Substances 0.000 claims description 19
- 229940002612 prodrug Drugs 0.000 claims description 19
- 125000004423 acyloxy group Chemical group 0.000 claims description 18
- 150000001356 alkyl thiols Chemical class 0.000 claims description 17
- 150000001540 azides Chemical class 0.000 claims description 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 17
- SOWBFZRMHSNYGE-UHFFFAOYSA-N oxamic acid Chemical compound NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 150000003573 thiols Chemical class 0.000 claims description 16
- 125000004001 thioalkyl group Chemical group 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000019695 Migraine disease Diseases 0.000 claims description 8
- 206010027599 migraine Diseases 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 7
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- DGDLNDSYBVZLMD-UHFFFAOYSA-N 7-cycloheptyl-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound O=C1CC2=CC=3OCOC=3C=C2C(C=2C=CC=CC=2)=NN1C1CCCCCC1 DGDLNDSYBVZLMD-UHFFFAOYSA-N 0.000 claims description 5
- PVRWPSHQDMPCRT-UHFFFAOYSA-N 7-cyclohexyl-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound O=C1CC2=CC=3OCOC=3C=C2C(C=2C=CC=CC=2)=NN1C1CCCCC1 PVRWPSHQDMPCRT-UHFFFAOYSA-N 0.000 claims description 5
- YUILGIPTMBBALO-UHFFFAOYSA-N 7-cyclopentyl-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound O=C1CC2=CC=3OCOC=3C=C2C(C=2C=CC=CC=2)=NN1C1CCCC1 YUILGIPTMBBALO-UHFFFAOYSA-N 0.000 claims description 5
- ZJIDUXXZCPEDAA-UHFFFAOYSA-N 7-pentan-3-yl-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C12=CC=3OCOC=3C=C2CC(=O)N(C(CC)CC)N=C1C1=CC=CC=C1 ZJIDUXXZCPEDAA-UHFFFAOYSA-N 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- UOQKSHZFTFBMOP-UHFFFAOYSA-N 5-phenyl-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound N=1NC(=O)CC2=CC=3OCOC=3C=C2C=1C1=CC=CC=C1 UOQKSHZFTFBMOP-UHFFFAOYSA-N 0.000 claims description 4
- HSXYLZKKCQPOJP-UHFFFAOYSA-N 5-phenyl-7-propan-2-yl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C12=CC=3OCOC=3C=C2CC(=O)N(C(C)C)N=C1C1=CC=CC=C1 HSXYLZKKCQPOJP-UHFFFAOYSA-N 0.000 claims description 4
- YCYQKANRLUEHHX-UHFFFAOYSA-N 7-hexan-3-yl-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C12=CC=3OCOC=3C=C2CC(=O)N(C(CC)CCC)N=C1C1=CC=CC=C1 YCYQKANRLUEHHX-UHFFFAOYSA-N 0.000 claims description 4
- QYIODSRZUOKBLF-UHFFFAOYSA-N 7-pentan-2-yl-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C12=CC=3OCOC=3C=C2CC(=O)N(C(C)CCC)N=C1C1=CC=CC=C1 QYIODSRZUOKBLF-UHFFFAOYSA-N 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 3
- RNLOLVZXAUQEBH-UHFFFAOYSA-N 5-(1,3-benzodioxol-5-yl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=C2C(C=3C=C4OCOC4=CC=3)=NNC(=O)CC2=CC2=C1OCO2 RNLOLVZXAUQEBH-UHFFFAOYSA-N 0.000 claims description 3
- NUTRNFDZGMEPPD-UHFFFAOYSA-N 5-[4-(methylamino)phenyl]-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=CC(NC)=CC=C1C(C1=C2)=NNC(=O)CC1=CC1=C2OCO1 NUTRNFDZGMEPPD-UHFFFAOYSA-N 0.000 claims description 3
- JWHSEKHZRCDHFD-UHFFFAOYSA-N 5-[4-(propan-2-ylamino)phenyl]-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=CC(NC(C)C)=CC=C1C(C1=C2)=NNC(=O)CC1=CC1=C2OCO1 JWHSEKHZRCDHFD-UHFFFAOYSA-N 0.000 claims description 3
- YEPOETYFFBTFEM-UHFFFAOYSA-N 6-phenyl-2,3,8,10-tetrahydro-[1,4]dioxino[2,3-h][2,3]benzodiazepin-9-one Chemical compound N=1NC(=O)CC2=CC=3OCCOC=3C=C2C=1C1=CC=CC=C1 YEPOETYFFBTFEM-UHFFFAOYSA-N 0.000 claims description 3
- 239000002841 Lewis acid Substances 0.000 claims description 3
- UAQQVNXIAZBQNM-UHFFFAOYSA-N chembl292377 Chemical compound C1=CC(O)=CC=C1C(C1=C2)=NNC(=O)CC1=CC1=C2OCO1 UAQQVNXIAZBQNM-UHFFFAOYSA-N 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 150000007517 lewis acids Chemical group 0.000 claims description 3
- MYZFXVFODBPWKR-UHFFFAOYSA-N n-[4-(9-methyl-8-oxo-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)phenyl]acetamide Chemical compound N=1NC(=O)C(C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(NC(C)=O)C=C1 MYZFXVFODBPWKR-UHFFFAOYSA-N 0.000 claims description 3
- KGVROGWGQGUTCZ-UHFFFAOYSA-N n-methyl-8-oxo-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepine-7-carboxamide Chemical compound C12=CC=3OCOC=3C=C2CC(=O)N(C(=O)NC)N=C1C1=CC=CC=C1 KGVROGWGQGUTCZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000007472 neurodevelopment Effects 0.000 claims description 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 2
- 150000004965 peroxy acids Chemical class 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 13
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 206010008748 Chorea Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000003678 AMPA Receptors Human genes 0.000 abstract description 20
- 108090000078 AMPA Receptors Proteins 0.000 abstract description 20
- 239000005557 antagonist Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 13
- 208000007101 Muscle Cramp Diseases 0.000 abstract description 4
- 208000005392 Spasm Diseases 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 abstract description 2
- 206010046543 Urinary incontinence Diseases 0.000 abstract description 2
- 208000001763 cytomegalovirus retinitis Diseases 0.000 abstract description 2
- 208000029726 Neurodevelopmental disease Diseases 0.000 abstract 1
- 239000002475 cognitive enhancer Substances 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 55
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 52
- 239000007787 solid Substances 0.000 description 50
- 239000000243 solution Substances 0.000 description 39
- 239000000203 mixture Substances 0.000 description 36
- 239000000460 chlorine Substances 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 235000019439 ethyl acetate Nutrition 0.000 description 25
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000011734 sodium Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 16
- 238000004587 chromatography analysis Methods 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 14
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 14
- 239000012267 brine Substances 0.000 description 13
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- HEMYXNDMAAOTCK-UHFFFAOYSA-N methyl 2-(1,3-benzodioxol-5-yl)acetate Chemical compound COC(=O)CC1=CC=C2OCOC2=C1 HEMYXNDMAAOTCK-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 229940098747 AMPA receptor antagonist Drugs 0.000 description 7
- 239000000775 AMPA receptor antagonist Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000001773 anti-convulsant effect Effects 0.000 description 6
- 239000001961 anticonvulsive agent Substances 0.000 description 6
- 229960003965 antiepileptics Drugs 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000002921 anti-spasmodic effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 229930195712 glutamate Natural products 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 102000018899 Glutamate Receptors Human genes 0.000 description 4
- 108010027915 Glutamate Receptors Proteins 0.000 description 4
- 208000010496 Heart Arrest Diseases 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 208000028389 Nerve injury Diseases 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 230000003492 excitotoxic effect Effects 0.000 description 4
- 231100000063 excitotoxicity Toxicity 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000000324 neuroprotective effect Effects 0.000 description 4
- 210000000287 oocyte Anatomy 0.000 description 4
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 229940049953 phenylacetate Drugs 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- XLIBPJGGWFXKDT-UHFFFAOYSA-N methyl 2-(6-benzoyl-1,3-benzodioxol-5-yl)acetate Chemical compound COC(=O)CC1=CC=2OCOC=2C=C1C(=O)C1=CC=CC=C1 XLIBPJGGWFXKDT-UHFFFAOYSA-N 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 230000008764 nerve damage Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 230000036963 noncompetitive effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
- PQNJPMUDXMYLQC-UHFFFAOYSA-N 3,5-dihydro-2,3-benzodiazepin-4-one Chemical compound C1=NNC(=O)CC2=CC=CC=C21 PQNJPMUDXMYLQC-UHFFFAOYSA-N 0.000 description 2
- ZCVAGTPWBAZXAL-UHFFFAOYSA-N 4-nitro-2,1,3-benzoxadiazole Chemical compound [O-][N+](=O)C1=CC=CC2=NON=C12 ZCVAGTPWBAZXAL-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- RPBDCDQMCRHNLM-UHFFFAOYSA-N C1=NNC=C2C=CC=CC2=C1 Chemical class C1=NNC=C2C=CC=CC2=C1 RPBDCDQMCRHNLM-UHFFFAOYSA-N 0.000 description 2
- VNRDMNYFMAAPRI-UHFFFAOYSA-N C1CCN(C1)C2=C(C=CC3=C2C(=O)NC3=O)N Chemical group C1CCN(C1)C2=C(C=CC3=C2C(=O)NC3=O)N VNRDMNYFMAAPRI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- IRJCBFDCFXCWGO-UHFFFAOYSA-N Ibotenic acid Chemical compound OC(=O)C(N)C1=CC(=O)NO1 IRJCBFDCFXCWGO-UHFFFAOYSA-N 0.000 description 2
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 229940124575 antispasmodic agent Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 210000003618 cortical neuron Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- ZUFFHFHJHSEHJI-UHFFFAOYSA-N methyl 2-(1,3-benzodioxol-5-yl)propanoate Chemical compound COC(=O)C(C)C1=CC=C2OCOC2=C1 ZUFFHFHJHSEHJI-UHFFFAOYSA-N 0.000 description 2
- CYRBFKRBYKJIBV-UHFFFAOYSA-N methyl 2-(6-benzoyl-1,3-benzodioxol-5-yl)propanoate Chemical compound COC(=O)C(C)C1=CC=2OCOC=2C=C1C(=O)C1=CC=CC=C1 CYRBFKRBYKJIBV-UHFFFAOYSA-N 0.000 description 2
- ZREPCAXZLIBMDG-UHFFFAOYSA-N methyl 2-[6-(2-chloro-4-nitrobenzoyl)-1,3-benzodioxol-5-yl]acetate Chemical compound COC(=O)CC1=CC=2OCOC=2C=C1C(=O)C1=CC=C([N+]([O-])=O)C=C1Cl ZREPCAXZLIBMDG-UHFFFAOYSA-N 0.000 description 2
- IEMQDQVIQIMCLA-UHFFFAOYSA-N methyl 2-[6-(3-methyl-4-nitrobenzoyl)-1,3-benzodioxol-5-yl]acetate Chemical compound COC(=O)CC1=CC=2OCOC=2C=C1C(=O)C1=CC=C([N+]([O-])=O)C(C)=C1 IEMQDQVIQIMCLA-UHFFFAOYSA-N 0.000 description 2
- VPJNVZORYJEMOC-UHFFFAOYSA-N methyl 2-[6-(3-nitrobenzoyl)-1,3-benzodioxol-5-yl]acetate Chemical compound COC(=O)CC1=CC=2OCOC=2C=C1C(=O)C1=CC=CC([N+]([O-])=O)=C1 VPJNVZORYJEMOC-UHFFFAOYSA-N 0.000 description 2
- XAIMYQGVNXSMPS-UHFFFAOYSA-N methyl 2-[6-(4-nitrobenzoyl)-1,3-benzodioxol-5-yl]acetate Chemical compound COC(=O)CC1=CC=2OCOC=2C=C1C(=O)C1=CC=C([N+]([O-])=O)C=C1 XAIMYQGVNXSMPS-UHFFFAOYSA-N 0.000 description 2
- HYDHNYHBKZFKBA-UHFFFAOYSA-N methyl 2-[6-(4-nitrobenzoyl)-1,3-benzodioxol-5-yl]propanoate Chemical compound COC(=O)C(C)C1=CC=2OCOC=2C=C1C(=O)C1=CC=C([N+]([O-])=O)C=C1 HYDHNYHBKZFKBA-UHFFFAOYSA-N 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000003961 neuronal insult Effects 0.000 description 2
- 239000004090 neuroprotective agent Substances 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- VDVJGIYXDVPQLP-UHFFFAOYSA-N piperonylic acid Chemical compound OC(=O)C1=CC=C2OCOC2=C1 VDVJGIYXDVPQLP-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- YFYNOWXBIBKGHB-MHTLYPKNSA-N (1r,3s)-1-aminocyclopentane-1,3-dicarboxylic acid Chemical compound OC(=O)[C@@]1(N)CC[C@H](C(O)=O)C1 YFYNOWXBIBKGHB-MHTLYPKNSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 1
- SWGZHHCRMZDRSN-BTJKTKAUSA-N (Z)-but-2-enedioic acid 1-phenoxypropan-2-ylhydrazine Chemical compound OC(=O)\C=C/C(O)=O.NNC(C)COC1=CC=CC=C1 SWGZHHCRMZDRSN-BTJKTKAUSA-N 0.000 description 1
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 description 1
- BAVAZRNEAWBRLO-UHFFFAOYSA-N 1,2-benzodiazepin-4-one Chemical compound O=C1C=NN=C2C=CC=CC2=C1 BAVAZRNEAWBRLO-UHFFFAOYSA-N 0.000 description 1
- DKVSKTKTDLSVSF-UHFFFAOYSA-N 1,3-benzodioxol-4-yl acetate Chemical compound CC(=O)OC1=CC=CC2=C1OCO2 DKVSKTKTDLSVSF-UHFFFAOYSA-N 0.000 description 1
- ABJFBJGGLJVMAQ-UHFFFAOYSA-N 1,4-dihydroquinoxaline-2,3-dione Chemical compound C1=CC=C2NC(=O)C(=O)NC2=C1 ABJFBJGGLJVMAQ-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BDNAXVKBARVSFE-UHFFFAOYSA-N 1-nitrocyclohexa-2,4-diene-1-carboxylic acid Chemical compound [N+](=O)([O-])C1(C(=O)O)CC=CC=C1 BDNAXVKBARVSFE-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- UQNAFPHGVPVTAL-UHFFFAOYSA-N 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+]([O-])=O)C1=C2C=CC=C1S(=O)(=O)N UQNAFPHGVPVTAL-UHFFFAOYSA-N 0.000 description 1
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- ODVLMCWNGKLROU-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)acetic acid Chemical compound OC(=O)CC1=CC=C2OCOC2=C1 ODVLMCWNGKLROU-UHFFFAOYSA-N 0.000 description 1
- QACSIGRQMJIHRY-UHFFFAOYSA-N 2-(8-oxo-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-7-yl)acetonitrile Chemical compound N=1N(CC#N)C(=O)CC2=CC=3OCOC=3C=C2C=1C1=CC=CC=C1 QACSIGRQMJIHRY-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- OFTKFKYVSBNYEC-UHFFFAOYSA-N 2-furoyl chloride Chemical compound ClC(=O)C1=CC=CO1 OFTKFKYVSBNYEC-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- PWURRRRGLCVBMX-UHFFFAOYSA-N 3-methoxy-4-nitrobenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1[N+]([O-])=O PWURRRRGLCVBMX-UHFFFAOYSA-N 0.000 description 1
- XDTTUTIFWDAMIX-UHFFFAOYSA-N 3-methyl-4-nitrobenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1[N+]([O-])=O XDTTUTIFWDAMIX-UHFFFAOYSA-N 0.000 description 1
- AFPHTEQTJZKQAQ-UHFFFAOYSA-N 3-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1 AFPHTEQTJZKQAQ-UHFFFAOYSA-N 0.000 description 1
- RQKDTQACQPHOQL-UHFFFAOYSA-N 3h-2,3-benzodiazepine Chemical compound C1=NNC=CC2=CC=CC=C21 RQKDTQACQPHOQL-UHFFFAOYSA-N 0.000 description 1
- RUBSCPARMVJNKX-UHFFFAOYSA-N 4-(8-methyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)aniline;hydrochloride Chemical compound Cl.C12=CC=3OCOC=3C=C2CC(C)=NN=C1C1=CC=C(N)C=C1 RUBSCPARMVJNKX-UHFFFAOYSA-N 0.000 description 1
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
- NQUVCRCCRXRJCK-UHFFFAOYSA-N 4-methylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1 NQUVCRCCRXRJCK-UHFFFAOYSA-N 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- PUPQHOLZSLGNHY-UHFFFAOYSA-N 5-(1,3-benzodioxol-5-yl)-9-methyl-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=C2C(C=3C=C4OCOC4=CC=3)=NNC(=O)C(C)C2=CC2=C1OCO2 PUPQHOLZSLGNHY-UHFFFAOYSA-N 0.000 description 1
- MCHGCRGPRCVASU-UHFFFAOYSA-N 5-(2-chloro-4-nitrophenyl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound ClC1=CC([N+](=O)[O-])=CC=C1C(C1=C2)=NNC(=O)CC1=CC1=C2OCO1 MCHGCRGPRCVASU-UHFFFAOYSA-N 0.000 description 1
- KPFXRIHQUAJTGZ-UHFFFAOYSA-N 5-(3-aminophenyl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound NC1=CC=CC(C=2C3=CC=4OCOC=4C=C3CC(=O)NN=2)=C1 KPFXRIHQUAJTGZ-UHFFFAOYSA-N 0.000 description 1
- AJZLKYQQUAEUOI-UHFFFAOYSA-N 5-(3-methoxy-4-nitrophenyl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(C=2C3=CC=4OCOC=4C=C3CC(=O)NN=2)=C1 AJZLKYQQUAEUOI-UHFFFAOYSA-N 0.000 description 1
- GNPBDWIPJVTVAW-UHFFFAOYSA-N 5-(3-methyl-4-nitrophenyl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=C([N+]([O-])=O)C(C)=CC(C=2C3=CC=4OCOC=4C=C3CC(=O)NN=2)=C1 GNPBDWIPJVTVAW-UHFFFAOYSA-N 0.000 description 1
- OODOSXSNJIXDPE-UHFFFAOYSA-N 5-(3-nitrophenyl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound [O-][N+](=O)C1=CC=CC(C=2C3=CC=4OCOC=4C=C3CC(=O)NN=2)=C1 OODOSXSNJIXDPE-UHFFFAOYSA-N 0.000 description 1
- PGSWTTFBYMJPCL-UHFFFAOYSA-N 5-(4-amino-2-chlorophenyl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound ClC1=CC(N)=CC=C1C(C1=C2)=NNC(=O)CC1=CC1=C2OCO1 PGSWTTFBYMJPCL-UHFFFAOYSA-N 0.000 description 1
- QVVNONKWKJQNKF-UHFFFAOYSA-N 5-(4-amino-3,5-dibromophenyl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=C(Br)C(N)=C(Br)C=C1C(C1=C2)=NNC(=O)CC1=CC1=C2OCO1 QVVNONKWKJQNKF-UHFFFAOYSA-N 0.000 description 1
- CZBDJHVALOXAER-UHFFFAOYSA-N 5-(4-amino-3,5-dichlorophenyl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=C(Cl)C(N)=C(Cl)C=C1C(C1=C2)=NNC(=O)CC1=CC1=C2OCO1 CZBDJHVALOXAER-UHFFFAOYSA-N 0.000 description 1
- JYNFHWFBLJPWAW-UHFFFAOYSA-N 5-(4-amino-3-chlorophenyl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=C(Cl)C(N)=CC=C1C(C1=C2)=NNC(=O)CC1=CC1=C2OCO1 JYNFHWFBLJPWAW-UHFFFAOYSA-N 0.000 description 1
- YIEUEASPZKQJMD-UHFFFAOYSA-N 5-(4-amino-3-methoxyphenyl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=C(N)C(OC)=CC(C=2C3=CC=4OCOC=4C=C3CC(=O)NN=2)=C1 YIEUEASPZKQJMD-UHFFFAOYSA-N 0.000 description 1
- MPBHCAPGFSEZTI-UHFFFAOYSA-N 5-(4-amino-3-methylphenyl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=C(N)C(C)=CC(C=2C3=CC=4OCOC=4C=C3CC(=O)NN=2)=C1 MPBHCAPGFSEZTI-UHFFFAOYSA-N 0.000 description 1
- FZBJYMKRNBONAQ-UHFFFAOYSA-N 5-(4-aminophenyl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=CC(N)=CC=C1C(C1=C2)=NNC(=O)CC1=CC1=C2OCO1 FZBJYMKRNBONAQ-UHFFFAOYSA-N 0.000 description 1
- LXDOQCWHWTTZGN-UHFFFAOYSA-N 5-(4-aminophenyl)-7-pentan-3-yl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C12=CC=3OCOC=3C=C2CC(=O)N(C(CC)CC)N=C1C1=CC=C(N)C=C1 LXDOQCWHWTTZGN-UHFFFAOYSA-N 0.000 description 1
- LFRNFUXNACAKBP-UHFFFAOYSA-N 5-(4-aminophenyl)-9-methyl-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound N=1NC(=O)C(C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 LFRNFUXNACAKBP-UHFFFAOYSA-N 0.000 description 1
- OKEOZZZPSQSQFH-UHFFFAOYSA-N 5-(4-azidophenyl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=CC(N=[N+]=[N-])=CC=C1C(C1=C2)=NNC(=O)CC1=CC1=C2OCO1 OKEOZZZPSQSQFH-UHFFFAOYSA-N 0.000 description 1
- BXDRDJZIBUACNN-UHFFFAOYSA-N 5-(4-fluorophenyl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=CC(F)=CC=C1C(C1=C2)=NNC(=O)CC1=CC1=C2OCO1 BXDRDJZIBUACNN-UHFFFAOYSA-N 0.000 description 1
- MEZDPFXANJUOGN-UHFFFAOYSA-N 5-(4-methoxyphenyl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=CC(OC)=CC=C1C(C1=C2)=NNC(=O)CC1=CC1=C2OCO1 MEZDPFXANJUOGN-UHFFFAOYSA-N 0.000 description 1
- KVMYOTKLAMTQJS-UHFFFAOYSA-N 5-(4-methylphenyl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=CC(C)=CC=C1C(C1=C2)=NNC(=O)CC1=CC1=C2OCO1 KVMYOTKLAMTQJS-UHFFFAOYSA-N 0.000 description 1
- BLLCLEKKZDQXMK-UHFFFAOYSA-N 5-(4-methylphenyl)-7-propan-2-yl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C12=CC=3OCOC=3C=C2CC(=O)N(C(C)C)N=C1C1=CC=C(C)C=C1 BLLCLEKKZDQXMK-UHFFFAOYSA-N 0.000 description 1
- YXTNHOZCRKJWQH-UHFFFAOYSA-N 5-(4-nitrophenyl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(C1=C2)=NNC(=O)CC1=CC1=C2OCO1 YXTNHOZCRKJWQH-UHFFFAOYSA-N 0.000 description 1
- ZEXQYVNXXRCIDN-UHFFFAOYSA-N 5-(furan-2-yl)-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound N=1NC(=O)CC2=CC=3OCOC=3C=C2C=1C1=CC=CO1 ZEXQYVNXXRCIDN-UHFFFAOYSA-N 0.000 description 1
- GPPBNSGDLDIPPV-UHFFFAOYSA-N 7-(2-hydroxyethyl)-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=C2CC(=O)N(CCO)N=CC2=CC2=C1OCO2 GPPBNSGDLDIPPV-UHFFFAOYSA-N 0.000 description 1
- FUSLZRYRJLURGZ-UHFFFAOYSA-N 7-(2-morpholin-4-ylethyl)-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound O=C1CC2=CC=3OCOC=3C=C2C(C=2C=CC=CC=2)=NN1CCN1CCOCC1 FUSLZRYRJLURGZ-UHFFFAOYSA-N 0.000 description 1
- KXBWRNCIHZYDKK-UHFFFAOYSA-N 7-(4-aminophenyl)-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=CC(N)=CC=C1N1C(=O)CC2=CC(OCO3)=C3C=C2C(C=2C=CC=CC=2)=N1 KXBWRNCIHZYDKK-UHFFFAOYSA-N 0.000 description 1
- MOBZXIDLOKYSRE-UHFFFAOYSA-N 7-(4-nitrophenyl)-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1C(=O)CC2=CC(OCO3)=C3C=C2C(C=2C=CC=CC=2)=N1 MOBZXIDLOKYSRE-UHFFFAOYSA-N 0.000 description 1
- YUATXBIBLPDFDU-UHFFFAOYSA-N 7-(cyclohexylmethyl)-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound O=C1CC2=CC=3OCOC=3C=C2C(C=2C=CC=CC=2)=NN1CC1CCCCC1 YUATXBIBLPDFDU-UHFFFAOYSA-N 0.000 description 1
- SLDIEIKHQBWIML-UHFFFAOYSA-N 7-[(4-methoxyphenyl)methyl]-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)CC2=CC(OCO3)=C3C=C2C(C=2C=CC=CC=2)=N1 SLDIEIKHQBWIML-UHFFFAOYSA-N 0.000 description 1
- XCMHBYCHURNWQF-UHFFFAOYSA-N 7-[2-(diethylamino)ethyl]-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one;hydrochloride Chemical compound Cl.C12=CC=3OCOC=3C=C2CC(=O)N(CCN(CC)CC)N=C1C1=CC=CC=C1 XCMHBYCHURNWQF-UHFFFAOYSA-N 0.000 description 1
- CMGXGYIKZHGLAP-UHFFFAOYSA-N 7-[2-(dimethylamino)ethyl]-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C12=CC=3OCOC=3C=C2CC(=O)N(CCN(C)C)N=C1C1=CC=CC=C1 CMGXGYIKZHGLAP-UHFFFAOYSA-N 0.000 description 1
- FOHUMFIQHBSPGD-UHFFFAOYSA-N 7-aminoisochromen-1-one Chemical compound C1=COC(=O)C2=CC(N)=CC=C21 FOHUMFIQHBSPGD-UHFFFAOYSA-N 0.000 description 1
- NVPHEDXCFLBOOA-UHFFFAOYSA-N 7-ethyl-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C12=CC=3OCOC=3C=C2CC(=O)N(CC)N=C1C1=CC=CC=C1 NVPHEDXCFLBOOA-UHFFFAOYSA-N 0.000 description 1
- PHKMGIAFOSQBNR-UHFFFAOYSA-N 7-heptan-4-yl-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C12=CC=3OCOC=3C=C2CC(=O)N(C(CCC)CCC)N=C1C1=CC=CC=C1 PHKMGIAFOSQBNR-UHFFFAOYSA-N 0.000 description 1
- LOVVEDJBUUIFOB-UHFFFAOYSA-N 7-methyl-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C12=CC=3OCOC=3C=C2CC(=O)N(C)N=C1C1=CC=CC=C1 LOVVEDJBUUIFOB-UHFFFAOYSA-N 0.000 description 1
- YEFNPUAKYJVJFD-UHFFFAOYSA-N 7-pentyl-5-phenyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound C12=CC=3OCOC=3C=C2CC(=O)N(CCCCC)N=C1C1=CC=CC=C1 YEFNPUAKYJVJFD-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- ZUMWWRNTKFKXBX-UHFFFAOYSA-N 9-methyl-5-phenyl-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-one Chemical compound N=1NC(=O)C(C)C2=CC=3OCOC=3C=C2C=1C1=CC=CC=C1 ZUMWWRNTKFKXBX-UHFFFAOYSA-N 0.000 description 1
- QAYNSPOKTRVZRC-UHFFFAOYSA-N 99-60-5 Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1Cl QAYNSPOKTRVZRC-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000024255 Audiogenic seizures Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000001408 Carbon monoxide poisoning Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- 206010008027 Cerebellar atrophy Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- LFBZZHVSGAHQPP-UHFFFAOYSA-N GYKI 52466 Chemical compound C12=CC=3OCOC=3C=C2CC(C)=NN=C1C1=CC=C(N)C=C1 LFBZZHVSGAHQPP-UHFFFAOYSA-N 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000005168 Intussusception Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical group N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000005903 Manganese Poisoning Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical group [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150084935 PTER gene Proteins 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- NVJCTUXUZPAIRY-UHFFFAOYSA-N [4-(8-oxo-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)phenyl]thiourea Chemical compound C1=CC(NC(=S)N)=CC=C1C(C1=C2)=NNC(=O)CC1=CC1=C2OCO1 NVJCTUXUZPAIRY-UHFFFAOYSA-N 0.000 description 1
- UAKIXRXZTCVFEA-UHFFFAOYSA-N [4-(8-oxo-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)phenyl]urea Chemical compound C1=CC(NC(=O)N)=CC=C1C(C1=C2)=NNC(=O)CC1=CC1=C2OCO1 UAKIXRXZTCVFEA-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000005165 aryl thioxy group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- GLZXFITXXAMCRJ-UHFFFAOYSA-N azepin-4-one Chemical compound O=C1C=CC=NC=C1 GLZXFITXXAMCRJ-UHFFFAOYSA-N 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 201000005682 chronic closed-angle glaucoma Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 208000029039 cyanide poisoning Diseases 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical class C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- CVLAEJNQNKXNNN-UHFFFAOYSA-N diazepin-4-one Chemical compound O=C1C=CC=NN=C1 CVLAEJNQNKXNNN-UHFFFAOYSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VZFRNCSOCOPNDB-AJKFJWDBSA-N domoic acid Chemical compound OC(=O)[C@@H](C)\C=C\C=C(/C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VZFRNCSOCOPNDB-AJKFJWDBSA-N 0.000 description 1
- VZFRNCSOCOPNDB-UHFFFAOYSA-N domoic acid Natural products OC(=O)C(C)C=CC=C(C)C1CNC(C(O)=O)C1CC(O)=O VZFRNCSOCOPNDB-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- VZFRNCSOCOPNDB-OXYNIABMSA-N isodomoic acid D Natural products CC(C=C/C=C(/C)C1CNC(C1CC(=O)O)C(=O)O)C(=O)O VZFRNCSOCOPNDB-OXYNIABMSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- JWEPCHGXAATSSG-UHFFFAOYSA-N methyl 2-[6-(1,3-benzodioxole-5-carbonyl)-1,3-benzodioxol-5-yl]propanoate Chemical compound C1=C2OCOC2=CC(C(=O)C2=CC=3OCOC=3C=C2C(C)C(=O)OC)=C1 JWEPCHGXAATSSG-UHFFFAOYSA-N 0.000 description 1
- CHWTWRBHKJJMHW-UHFFFAOYSA-N methyl 2-[6-(3-methoxy-4-nitrobenzoyl)-1,3-benzodioxol-5-yl]acetate Chemical compound COC(=O)CC1=CC=2OCOC=2C=C1C(=O)C1=CC=C([N+]([O-])=O)C(OC)=C1 CHWTWRBHKJJMHW-UHFFFAOYSA-N 0.000 description 1
- JSCZANNMYBUKJA-UHFFFAOYSA-N methyl 2-[6-(4-fluorobenzoyl)-1,3-benzodioxol-5-yl]acetate Chemical compound COC(=O)CC1=CC=2OCOC=2C=C1C(=O)C1=CC=C(F)C=C1 JSCZANNMYBUKJA-UHFFFAOYSA-N 0.000 description 1
- NGXNADOTFBPSML-UHFFFAOYSA-N methyl 2-[6-(4-methoxybenzoyl)-1,3-benzodioxol-5-yl]acetate Chemical compound COC(=O)CC1=CC=2OCOC=2C=C1C(=O)C1=CC=C(OC)C=C1 NGXNADOTFBPSML-UHFFFAOYSA-N 0.000 description 1
- XTWPYPVQQFQLDB-UHFFFAOYSA-N methyl 2-[6-(4-methylbenzoyl)-1,3-benzodioxol-5-yl]acetate Chemical compound COC(=O)CC1=CC=2OCOC=2C=C1C(=O)C1=CC=C(C)C=C1 XTWPYPVQQFQLDB-UHFFFAOYSA-N 0.000 description 1
- BQAWAAHICXXJKU-UHFFFAOYSA-N methyl 2-[6-(furan-2-carbonyl)-1,3-benzodioxol-5-yl]acetate Chemical compound COC(=O)CC1=CC=2OCOC=2C=C1C(=O)C1=CC=CO1 BQAWAAHICXXJKU-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000007625 mitochondrial abnormality Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- XAWRFNNHUHTBGT-UHFFFAOYSA-N n-[4-(8-oxo-7,9-dihydro-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C(C1=C2)=NNC(=O)CC1=CC1=C2OCO1 XAWRFNNHUHTBGT-UHFFFAOYSA-N 0.000 description 1
- VFIXRYJOPPBPOY-UHFFFAOYSA-N n-methyl-5-(4-nitrophenyl)-8-oxo-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepine-7-carboxamide Chemical compound C12=CC=3OCOC=3C=C2CC(=O)N(C(=O)NC)N=C1C1=CC=C([N+]([O-])=O)C=C1 VFIXRYJOPPBPOY-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000001379 nervous effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005152 pentetrazol Drugs 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- RVEZZJVBDQCTEF-UHFFFAOYSA-N sulfenic acid Chemical compound SO RVEZZJVBDQCTEF-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/02—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1381396P | 1996-03-21 | 1996-03-21 | |
| US60/013,813 | 1996-03-21 | ||
| PCT/US1997/003462 WO1997034878A1 (en) | 1996-03-21 | 1997-03-21 | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000506890A true JP2000506890A (ja) | 2000-06-06 |
| JP2000506890A5 JP2000506890A5 (enExample) | 2004-12-02 |
Family
ID=21761900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9533496A Ceased JP2000506890A (ja) | 1996-03-21 | 1997-03-21 | 置換２，３―ベンゾジアゼピン―４―オンおよびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5891871A (enExample) |
| EP (1) | EP1021418B1 (enExample) |
| JP (1) | JP2000506890A (enExample) |
| AT (1) | ATE267177T1 (enExample) |
| AU (1) | AU2527097A (enExample) |
| DE (1) | DE69729227T2 (enExample) |
| DK (1) | DK1021418T3 (enExample) |
| ES (1) | ES2217406T3 (enExample) |
| PT (1) | PT1021418E (enExample) |
| WO (1) | WO1997034878A1 (enExample) |
| ZA (1) | ZA972496B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007509883A (ja) * | 2003-10-28 | 2007-04-19 | ノバルティス アクチエンゲゼルシャフト | 統合失調症の処置のためのａｍｐａ受容体アンタゴニストを含む組み合わせ |
| JP2007153755A (ja) * | 2005-12-01 | 2007-06-21 | Gifu Univ | プロリン類縁体 |
| JP2012188422A (ja) * | 2011-03-08 | 2012-10-04 | Lab Servier | 新規ジヒドロ−オキサゾロベンゾジアゼピノン化合物、それらの調製方法およびそれらを含有する医薬組成物 |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19604919A1 (de) | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
| DE19604920A1 (de) * | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
| US6635632B1 (en) * | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| HU227128B1 (en) * | 1999-07-07 | 2010-07-28 | Egyt Gyogyszervegyeszeti Gyar | New 2,3-benzodiazepine derivatives |
| DE10004572A1 (de) * | 2000-02-02 | 2001-08-09 | Boehringer Ingelheim Pharma | Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2001096308A1 (en) | 2000-06-12 | 2001-12-20 | Eisai Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| US6432944B1 (en) | 2000-07-06 | 2002-08-13 | Bristol-Myers Squibb Company | Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives |
| HU225100B1 (hu) * | 2000-12-21 | 2006-06-28 | Egyt Gyogyszervegyeszeti Gyar | 2,3-Benzodiazepinszármazékok, ilyen hatóanyagot tartalmazó gyógyászati készítmények és alkalmazásuk |
| US6649607B2 (en) | 2001-05-18 | 2003-11-18 | Vela Pharmaceuticals, Inc. | Compositions and methods for treating or preventing convulsions or seizures |
| JP2005503356A (ja) * | 2001-06-07 | 2005-02-03 | ニューロ３デー | 環状ヌクレオチドホスホジエステラーゼ阻害剤、その製造および使用 |
| GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| US6864251B2 (en) * | 2002-12-03 | 2005-03-08 | Vela Pharmaceuticals, Inc. | Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines |
| US6638928B1 (en) | 2002-12-03 | 2003-10-28 | Vela Pharmaceuticals, Inc. | Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines |
| US7745431B2 (en) * | 2002-12-03 | 2010-06-29 | Vela Acquisition Corporation | Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereof |
| US7022700B2 (en) * | 2002-12-03 | 2006-04-04 | Vela Pharmaceuticals, Inc. | Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines |
| WO2004069155A2 (en) * | 2002-12-03 | 2004-08-19 | Vela Pharmaceuticals, Inc. | Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine and uses therof |
| PL378366A1 (pl) | 2003-01-13 | 2006-04-03 | Cortex Pharmaceuticals, Inc. | Sposób leczenia osłabienia funkcji poznawczych spowodowanego deprywacją snu i stresem |
| US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
| US20040224943A1 (en) * | 2003-02-19 | 2004-11-11 | Leventer Steven M. | Method of lowering body temperature with (R) - 2,3-benzodiazepines |
| US20040162284A1 (en) * | 2003-02-19 | 2004-08-19 | Harris Herbert W. | Method of lowering body temperature with (S) tofisopam |
| MY148809A (en) | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
| EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
| JP6333251B2 (ja) | 2012-08-16 | 2018-05-30 | バイエル ファーマ アクチエンゲゼルシャフト | ２，３−ベンゾジアゼピン類 |
| CA2901352A1 (en) | 2013-02-19 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines |
| CA2901805A1 (en) | 2013-02-22 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | 4-substituted pyrrolo- and pyrazolo-diazepines |
| HK1212972A1 (zh) | 2013-02-22 | 2016-06-24 | Bayer Pharma Aktiengesellschaft | 作爲bet-蛋白抑制剂用於治疗过度增殖性疾病的吡咯并-和吡唑并-三唑并二氮杂卓 |
| EP3311842A1 (en) | 2013-06-13 | 2018-04-25 | VeroScience LLC | Compositions and methods for treating metabolic disorders |
| EP3436021B1 (en) | 2016-03-29 | 2026-07-29 | RespireRx Pharmaceuticals, Inc. | Compositions comprising low impact ampakines for treating attention deficit disorders |
| WO2020124090A1 (en) | 2018-12-14 | 2020-06-18 | Eisai R&D Management Co., Ltd. | Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2085645A1 (en) * | 1970-04-22 | 1971-12-31 | Chimidrog | 1-phenyl-2,3-benzodiazepin-4-ones - as tranquillizers |
| HU191698B (en) * | 1984-07-27 | 1987-03-30 | Gyogyszerkutato Intezet | Process for producing new 1-aryl-5h-2beta-benzodiazepines |
| HU198494B (en) * | 1986-08-15 | 1989-10-30 | Gyogyszerkutato Intezet | Process for producing new 3,4-dihydro-5h-2,3-benzodiazepine derivative and acid addition salts thereof, as well as pharmaceutical compositions comprising same |
| HU219778B (hu) * | 1990-12-21 | 2001-07-30 | Gyógyszerkutató Intézet Közös Vállalat | Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények |
| US5550124A (en) * | 1991-12-10 | 1996-08-27 | University Of Southern California | Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease |
| US5922773A (en) * | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
| DE19604920A1 (de) * | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
-
1997
- 1997-03-20 US US08/821,638 patent/US5891871A/en not_active Expired - Fee Related
- 1997-03-21 AT AT97916722T patent/ATE267177T1/de not_active IP Right Cessation
- 1997-03-21 DE DE69729227T patent/DE69729227T2/de not_active Expired - Fee Related
- 1997-03-21 WO PCT/US1997/003462 patent/WO1997034878A1/en not_active Ceased
- 1997-03-21 ES ES97916722T patent/ES2217406T3/es not_active Expired - Lifetime
- 1997-03-21 JP JP9533496A patent/JP2000506890A/ja not_active Ceased
- 1997-03-21 AU AU25270/97A patent/AU2527097A/en not_active Abandoned
- 1997-03-21 DK DK97916722T patent/DK1021418T3/da active
- 1997-03-21 PT PT97916722T patent/PT1021418E/pt unknown
- 1997-03-21 EP EP97916722A patent/EP1021418B1/en not_active Expired - Lifetime
- 1997-03-24 ZA ZA9702496A patent/ZA972496B/xx unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007509883A (ja) * | 2003-10-28 | 2007-04-19 | ノバルティス アクチエンゲゼルシャフト | 統合失調症の処置のためのａｍｐａ受容体アンタゴニストを含む組み合わせ |
| JP2007153755A (ja) * | 2005-12-01 | 2007-06-21 | Gifu Univ | プロリン類縁体 |
| JP2012188422A (ja) * | 2011-03-08 | 2012-10-04 | Lab Servier | 新規ジヒドロ−オキサゾロベンゾジアゼピノン化合物、それらの調製方法およびそれらを含有する医薬組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| PT1021418E (pt) | 2004-10-29 |
| US5891871A (en) | 1999-04-06 |
| ZA972496B (en) | 1997-10-02 |
| DE69729227T2 (de) | 2005-05-04 |
| DK1021418T3 (da) | 2004-09-20 |
| ATE267177T1 (de) | 2004-06-15 |
| AU2527097A (en) | 1997-10-10 |
| DE69729227D1 (de) | 2004-06-24 |
| WO1997034878A1 (en) | 1997-09-25 |
| EP1021418A4 (en) | 2001-06-13 |
| EP1021418A1 (en) | 2000-07-26 |
| EP1021418B1 (en) | 2004-05-19 |
| ES2217406T3 (es) | 2004-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5891871A (en) | Substituted 2,3-benzodiazepin-4-ones and the use thereof | |
| DE60014851T2 (de) | Anti-imflammtorische indolderivate | |
| RU2152388C1 (ru) | Трициклические производные пиразола | |
| DE69315920T2 (de) | Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung | |
| US6765006B2 (en) | Substituted quinazolines and analogs and the use thereof | |
| JP2756742B2 (ja) | Ｎ−アシル−２，３−ベンゾジアゼピン誘導体、その製造法、それを含有する医薬組成物、およびその製造法 | |
| DE60208221T2 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
| EA002113B1 (ru) | Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно) | |
| EP1599167A2 (fr) | Derives de benzimidazole et d'imidazo-pyridine ayant une affinite pour les recepteurs des melanocortines et leur utilisation en tant que medicament | |
| CZ304702B6 (cs) | (4R) a (4S) diastereoizomery (2S)-2-[2-oxo-4-propylpyrrolidinyl] butanamidu, farmaceutická kompozice s jejich obsahem a jejich použití | |
| EP0642513A1 (de) | Indolocarbazol-imide und deren verwendung | |
| WO2007091570A1 (ja) | スフィンゴシン－１－リン酸結合阻害物質 | |
| CA2050962A1 (en) | Aryl-fused and hetaryl-fused-2,4 diazepine and 2,4-diazocine antiarrhythmic agents | |
| JP2010530406A (ja) | 統合失調症の処置における使用のためのシンノリン化合物 | |
| CN112996783A (zh) | 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| CN108467386B (zh) | 稠杂芳基取代的1,2,4-三嗪-3-胺类衍生物、其制备方法及其在医药上的应用 | |
| JP2001512124A (ja) | 新規な２，３−ベンゾジアゼピン誘導体 | |
| EA008797B1 (ru) | Новые соединения бензотиазина и бензотиадиазина, способ их получения и фармацевтические композиции, которые их содержат | |
| US5500442A (en) | Cyclobut-3-ene-1,2-dione derivatives as smooth muscle relaxants | |
| JP4201252B2 (ja) | 新規な２，３−ベンゾジアゼピン誘導体及び該誘導体を有効成分として含有する医薬組成物 | |
| JP3128750B2 (ja) | １−［２−（置換ビニル）］−５ｈ−２，３−ベンゾジアゼピン誘導体 | |
| UA72261C2 (uk) | Похідні 2,3-бензодіазепіну | |
| EP1274689A2 (en) | Sulfur containing dihydrophthalazine antagonists of excitatory amino acid receptors | |
| MXPA96006228A (en) | Cyclubut-3-in-1,2-diona derivatives as relaxing muscles li | |
| JPWO1996025416A1 (ja) | チオフェン化合物およびその医薬用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040312 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040312 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071218 |
|
| A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20080520 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080722 |